Roche said its Ocrevus treatment showed fewer patients with relapsing multiple sclerosis needed walking aids, the company said on Wednesday. 

There was a 35 per cent reduction in the need for a walking aid in patients with relapsing Multiple Sclerosis (MS) after seven and a half years of taking Ocrevus, the company said. There was also a 29 per cent reduction in the 48-week progression in primary progressive MS after 8 years after starting taking the drug, it added.

(Reuters)